Hepatitis B Market By Key Manufacturers, By Product (Hepatitis B Vaccine, Antiviral Drugs), By Therapy (Chemotherapy, Immunosuppressant Therapy, Nucleoside Analogue), By Distribution Channel (Hospitals, Retail, Online) and By Regions (North America, Europe, Middle East and Africa, Latin America and Asia Pacific) - Global Outlook to 2026
Report ID: 91855 | Mar 2019 | No. of Pages: 120 |

Global Hepatitis B market is expected to register a CAGR of 5.8% during the forecast period 2018 to 2026. Hepatitis B is a life threatening infection of the liver caused by the virus called as Hepatitis B virus. If the infection in a patient lasts for short time, then the patient is said to have acute hepatitis B, however, if it lasts for a long time then the patient is referred to have chronic hepatitis B infection. Chronic hepatitis B infection generally occurs in infants and young children.
Hepatitis B Market Dynamics
The global Hepatitis B market is driven owing to the limited access to diagnosis and treatment of hepatitis B infection coupled with the significant rise in the prevalence of hepatitis B infection. In addition, rising awareness and an increase in the affordability of the diseases and its treatment are also factors that bolster the global hepatitis B market. Lastly, limited availability of antibiotics and the effectiveness of antivirals against hepatitis B infections is further expected to boost the demand and the need for hepatitis B vaccine.
Hepatitis B Market Insight
North America dominated the global Hepatitis B market due to high awareness among people, favourable government initiatives, and the availability of good healthcare infrastructure. Europe is the second largest market for hepatitis B followed by the Asia Pacific region. Middle East & Africa and Latin America occupy smaller shares of the market.
Hepatitis B Market Segmentation
The global Hepatitis B market is segmented into product, therapy, distribution channel and region. On the basis of the product the market is further bifurcated into Hepatitis B vaccine and antiviral drugs. On the basis of therapy, the global Hepatitis B market is categorized into Chemotherapy, Immunosuppressant Therapy, and Nucleoside Analogue. In addition, the global Hepatitis B market is classified on the basis of distribution channel into hospitals, retail and online pharmacies. Based on the geography the market is further segregated into North America, Latin America, Europe and Asia Pacific.
Hepatitis B Market Competitive Landscape
The major players associated with the global Hepatitis B market are GlaxoSmithKline plc, Gilead; Johnson & Johnson; Merck & Co.; Bristol-Myers Squibb; Novira Therapeutics, Abivax SA, Novartis AG, F. Hoffmann- La Roche, and AbbVie Inc. among others.

Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1.Research Approach
2.2. Data Distribution Channels
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
Chapter 4. Market Outlook
4.1. Market Dynamics
4.1.1. Market Drivers
4.1.2. Market Restraints
4.1.3. Market Opportunities
4.2. Porter’s Analysis
4.3. Value Chain Analysis
Chapter 5. Hepatitis B Market, By Product
5.1. Hepatitis B Market, by Product, 2018-2026
5.1.1. Hepatitis B Vaccine
5.1.2. Antiviral Drugs
Chapter 6. Hepatitis B Market, By Therapy
6.1. Hepatitis B Market, by Therapy, 2018-2026
6.1.1. Chemotherapy
6.1.2. Immunosuppressant Therapy
6.1.3. Nucleoside Analogue
Chapter 7. Hepatitis B Market, By Distribution Channel
7.1. Hepatitis B Market, by Distribution Channel, 2018-2026
7.1.1. Retail
7.1.2. Hospitals
7.1.3. Online
Chapter 8. Hepatitis B Market, By Region
8.1. Hepatitis B Market, by Region, 2018-2026
8.1.1. North America
8.1.1.1. U.S
8.1.1.2. Rest of North America
8.1.2. Europe
8.1.2.1. U.K.
8.1.2.2. Germany
8.1.2.3. France
8.1.2.4. Rest of the Europe
8.1.3. Middle East & Africa (MEA)
8.1.3.1. GCC
8.1.3.2. North Africa
8.1.3.3. South Africa
8.1.3.4. Rest of MEA
8.1.4. Latin America (LATAM)
8.1.4.1. Brazil
8.1.4.2. Rest of LATAM
8.1.5. Asia Pacific (APAC)
8.1.5.1. India
8.1.5.2. China
8.1.5.3. Japan
8.1.5.4. Rest of the APAC
Chapter 9. Competitive Landscape
9.1.1. Key Strategies Adopted by Players
9.1.2. Market Share/Positioning Analysis
Chapter 10. Company Profiles
10.1. GlaxoSmithKline plc
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Bristol-Myers Squibb
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Novira Therapeutics
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Johnson & Johnson
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Abivax SA
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. F. Hoffmann-La Roche
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Novartis AG
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Merck & Co.
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Gilead
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. AbbVie Inc.
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Appendix
11.1. About Us
11.2. Glossary of Terms
GlaxoSmithKline Plc
Gilead
Johnson & Johnson
Merck & Co.
Bristol-Myers Squibb
Novira Therapeutics
Abivax SA
Novartis AG
F. Hoffmann- La Roche
AbbVie Inc.

Select License Type
USD $4250
USD $6250
Connect With Us

+1-707-633-0404